Get the Stockscreener App
150.08
1.47%
2.1941
Overview
News
Price History
Option Chain
Financials
Why ORCL Down?
Discussions
Forecast
Stock Split
Dividend History
Oracle Corp stock is traded at $150.08, with a volume of 20.09M.
It is up +1.47% in the last 24 hours and down -17.75% over the past month.
Oracle provides enterprise applications and infrastructure offerings through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used by the world's largest companies for high-volume online transaction processing workloads. Besides databases, Oracle also sells enterprise resource planning platforms and cloud infrastructure that play an increasingly important role in large language model training and inferencing.
See More
Previous Close:
$147.89
Open:
$148.79
24h Volume:
20.09M
Relative Volume:
0.72
Market Cap:
$431.17B
Revenue:
$61.02B
Net Income/Loss:
$15.61B
P/E Ratio:
28.21
EPS:
5.3211
Net Cash Flow:
$-13.18B
1W Performance:
-4.14%
1M Performance:
-17.75%
6M Performance:
-35.93%
1Y Performance:
-12.99%
1-Day Range:
$145.15
$152.50
1-Week Range:
$138.59
$153.99
52-Week Range:
$118.86
$345.72
Oracle Corp Stock (ORCL) Company Profile
Name
Oracle Corp
Sector
Industry
Phone
(737) 867-1000
Address
2300 ORACLE WAY, AUSTIN, CA
Compare ORCL vs MSFT, PLTR, CRWD, SNPS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORCL
Oracle Corp
|
150.02 | 425.05B | 61.02B | 15.61B | -13.18B | 5.3211 |
|
MSFT
Microsoft Corporation
|
401.48 | 2.97T | 305.45B | 119.26B | 77.41B | 15.98 |
|
PLTR
Palantir Technologies Inc
|
135.71 | 320.94B | 4.48B | 1.63B | 2.10B | 0.6328 |
|
CRWD
Crowdstrike Holdings Inc
|
380.65 | 91.59B | 4.57B | -315.36M | 1.10B | -1.2634 |
|
SNPS
Synopsys Inc
|
429.15 | 85.93B | 7.05B | 1.34B | 1.35B | 8.0234 |
Oracle Corp Stock (ORCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | DA Davidson | Neutral → Buy |
| Feb-09-26 | Downgrade | Melius | Buy → Hold |
| Feb-04-26 | Reiterated | BMO Capital Markets | Outperform |
| Jan-12-26 | Resumed | Goldman | Buy |
| Dec-11-25 | Reiterated | BMO Capital Markets | Outperform |
| Dec-03-25 | Initiated | Wells Fargo | Overweight |
| Nov-10-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-13-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-09-25 | Initiated | Robert W. Baird | Outperform |
| Sep-25-25 | Initiated | Rothschild & Co Redburn | Sell |
| Sep-10-25 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-25 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Sep-09-25 | Reiterated | BMO Capital Markets | Outperform |
| Jul-17-25 | Initiated | Scotiabank | Sector Outperform |
| Jul-10-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-02-25 | Reiterated | BMO Capital Markets | Outperform |
| Jun-30-25 | Upgrade | Stifel | Hold → Buy |
| Jun-18-25 | Reiterated | Guggenheim | Buy |
| Jun-13-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-09-25 | Reiterated | BMO Capital Markets | Market Perform |
| Apr-23-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-19-25 | Initiated | Stephens | Equal-Weight |
| Mar-11-25 | Reiterated | BMO Capital Markets | Market Perform |
| Mar-03-25 | Upgrade | Monness Crespi & Hardt | Sell → Neutral |
| Jan-17-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Downgrade | Monness Crespi & Hardt | Neutral → Sell |
| Oct-23-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-16-24 | Upgrade | Melius | Hold → Buy |
| Sep-10-24 | Reiterated | BMO Capital Markets | Market Perform |
| Sep-10-24 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jun-17-24 | Reiterated | BMO Capital Markets | Market Perform |
| Apr-18-24 | Initiated | Oppenheimer | Perform |
| Mar-21-24 | Initiated | KeyBanc Capital Markets | Overweight |
| Mar-14-24 | Upgrade | Argus | Hold → Buy |
| Mar-12-24 | Reiterated | BMO Capital Markets | Market Perform |
| Mar-12-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-12-23 | Reiterated | BMO Capital Markets | Market Perform |
| Nov-13-23 | Upgrade | Edward Jones | Hold → Buy |
| Oct-09-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-15-23 | Initiated | HSBC Securities | Buy |
| Sep-14-23 | Upgrade | DZ Bank | Hold → Buy |
| Sep-13-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-12-23 | Downgrade | Monness Crespi & Hardt | Buy → Neutral |
| Sep-05-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-29-23 | Upgrade | UBS | Neutral → Buy |
| Jun-13-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-12-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-20-23 | Reiterated | KeyBanc Capital Markets | Overweight |
| Mar-10-23 | Downgrade | Societe Generale | Buy → Hold |
| Jan-18-23 | Initiated | DA Davidson | Neutral |
| Jan-11-23 | Initiated | Mizuho | Buy |
| Jan-09-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-05-23 | Upgrade | Jefferies | Hold → Buy |
| Oct-21-22 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Oct-20-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Sep-14-22 | Initiated | Berenberg | Hold |
| Aug-12-22 | Initiated | Guggenheim | Buy |
| Jun-29-22 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Jun-27-22 | Resumed | Goldman | Sell |
| Jun-14-22 | Reiterated | Monness Crespi & Hardt | Buy |
| Apr-01-22 | Initiated | Daiwa Securities | Neutral |
| Mar-29-22 | Downgrade | Exane BNP Paribas | Neutral → Underperform |
| Mar-11-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-11-22 | Upgrade | Societe Generale | Hold → Buy |
| Dec-21-21 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Dec-15-21 | Upgrade | DZ Bank | Sell → Hold |
| Dec-10-21 | Reiterated | BMO Capital Markets | Market Perform |
| Dec-10-21 | Reiterated | Barclays | Equal Weight |
| Dec-10-21 | Reiterated | Citigroup | Neutral |
| Dec-10-21 | Reiterated | Cowen | Outperform |
| Dec-10-21 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-10-21 | Reiterated | Monness Crespi & Hardt | Buy |
| Dec-10-21 | Reiterated | Piper Sandler | Neutral |
| Dec-10-21 | Reiterated | Societe Generale | Hold |
| Dec-10-21 | Reiterated | Stifel | Hold |
| Dec-10-21 | Reiterated | UBS | Neutral |
| Dec-10-21 | Reiterated | Wolfe Research | Peer Perform |
| Nov-16-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Deutsche Bank | Hold |
| Sep-14-21 | Reiterated | BMO Capital Markets | Market Perform |
| Sep-14-21 | Reiterated | Monness Crespi & Hardt | Buy |
| Aug-10-21 | Downgrade | DZ Bank | Hold → Sell |
| May-10-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-23-21 | Initiated | Wolfe Research | Peer Perform |
| Apr-21-21 | Downgrade | DZ Bank | Buy → Hold |
| Apr-01-21 | Resumed | Wedbush | Neutral |
| Mar-22-21 | Resumed | Evercore ISI | In-line |
| Mar-16-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Reiterated | Monness Crespi & Hardt | Buy |
| Mar-11-21 | Downgrade | Societe Generale | Buy → Hold |
| Mar-05-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-03-21 | Resumed | Citigroup | Neutral |
| Jan-22-21 | Initiated | Goldman | Sell |
| Dec-18-20 | Upgrade | Monness Crespi & Hardt | Neutral → Buy |
| Dec-16-20 | Resumed | BofA Securities | Neutral |
| Dec-08-20 | Downgrade | Cleveland Research | Buy → Neutral |
| Nov-24-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-14-20 | Resumed | UBS | Neutral |
| Sep-21-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-11-20 | Reiterated | BMO Capital Markets | Market Perform |
| Sep-11-20 | Reiterated | Barclays | Equal Weight |
| Sep-11-20 | Reiterated | Credit Suisse | Outperform |
| Sep-11-20 | Reiterated | Goldman | Buy |
| Sep-11-20 | Reiterated | Jefferies | Hold |
| Sep-11-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Sep-11-20 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-11-20 | Reiterated | Stifel | Hold |
| Sep-11-20 | Reiterated | Wells Fargo | Overweight |
| Jun-19-20 | Downgrade | Argus | Buy → Hold |
| Jun-01-20 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Mar-31-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-20-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-13-20 | Reiterated | BMO Capital Markets | Market Perform |
View All
Oracle Corp Stock (ORCL) Latest News
Healthcare Predictive Analytics Market Size to Reach USD 140.02 Billion by 2035; Growth is Driven by the Increasing EHR Volumes Globally - GlobeNewswire Inc.
ORCL Investors Have Opportunity to Lead Oracle Corporation Securities Fraud Lawsuit - Morningstar
Is Oppenheimer’s Upgrade a Turning Point in Oracle’s (ORCL) AI Infrastructure Risk Narrative? - simplywall.st
Is Oracle Corporation (ORCL) The Best Stock In Technology Sector? - Insider Monkey
Oracle's Selloff Offers a Chance to Buy an 'Upper-echelon' Growth Stock for Cheap, Analyst Says - 富途牛牛
Why Oracle Stock Bumped Higher on Wednesday - The Globe and Mail
Oracle stock edges up after Oppenheimer upgrade; what ORCL investors watch next - TechStock²
Micron vs. Oracle: One AI Stock Is a Clear Buy Right Now - The Globe and Mail
Oracle Corporation (NYSE:ORCL) Spending Growth Story And S&P 500 Futures Trend Watch - Kalkine Media
Oracle Stock Jumps on Top Analyst Ugrade -- Oppenheimer Sees $18 - GuruFocus
Amazon, Google, Meta, Microsoft, Oracle will agree to “build, bring, or buy” AI data center power - Sherwood News
Buy Oracle Stock, Analyst Says. Here’s Why. - Barron's
Oracle Upgraded to Buy at Oppenheimer After Selloff - GuruFocus
Oracle Stock Is Climbing Today: What's Happening? - Benzinga
Oracle's Projected Earnings Growth Likely to Drive Positive Sentiment Shift, Oppenheimer Says - marketscreener.com
Oracle stock jumps after Oppenheimer upgrade — what’s next for ORCL - TechStock²
Why Oracle stock is up around 3% today - Invezz
Oracle Health Launches Device Validation Program to Streamline Medical Device Integration and Accelerate Innovation in Healthcare - Oracle
Oracle Lawsuit Puts AI Infrastructure Spending And Disclosure Risks In Focus - Yahoo Finance
Oracle’s AI Pain May Be Over. Buy the Stock, Analysts Say. - Barron's
Is Oracle Stock Losing Its AI Edge? - Forbes
Oracle (ORCL) Upgraded by Oppenheimer with Strong EPS Growth Out - GuruFocus
Oracle's Stock Selloff Offers a Chance to Buy an 'Upper-echelon' Growth Play for Cheap: Analyst - 富途牛牛
Oracle’s selloff offers a chance to buy an ‘upper-echelon’ growth stock for cheap, analyst says - MarketWatch
SC&H Expands Oracle Cloud Capabilities with Addition of Industry Veteran Rich Reid - citybiz
Oracle and Netflix among market cap stock movers on Wednesday By Investing.com - Investing.com Canada
Oracle and Netflix among market cap stock movers on Wednesday - Investing.com
Oracle rises after upgrade at Oppenheimer - Seeking Alpha
Oracle Stock Upgraded To Buy As Analyst Sees Upside Following Sell Off - Investor's Business Daily
This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Oppenheimer upgrades Oracle stock rating on AI strength, sets $185 target - Investing.com Nigeria
Oracle upgraded, Workday downgraded: Wall Street's top analyst calls - Yahoo Finance
Ellison family's media empire expands: Oracle owner now targets Warner Bros. Discovery - Yeni Safak English
Oracle Stock Too Cheap to Ignore. Buy the Dip, Says Analyst. - Barron's
Oracle (NYSE:ORCL) Upgraded to "Outperform" at Oppenheimer - MarketBeat
Oracle Corporation $ORCL Shares Bought by TD Asset Management Inc - MarketBeat
Weitz Investment Management Inc. Sells 100,075 Shares of Oracle Corporation $ORCL - MarketBeat
Oppenheimer Upgrades Oracle (ORCL) - Nasdaq
Expert Outlook: Oracle Through The Eyes Of 27 Analysts - Benzinga
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More - 24/7 Wall St.
Oppenheimer Upgrades Oracle (ORCL) to 'Outperform' with New Pric - GuruFocus
Is Oracle Stock a Millionaire Maker? - AOL.com
It's time to buy Oracle shares after the sell-off, says Oppenheimer - CNBC
The Risk Factors to Watch Out For in Oracle Stock - Trefis
Bradley Foster & Sargent Inc. CT Increases Stake in Oracle Corporation $ORCL - MarketBeat
Southeast Georgia Health transforms healthcare with Oracle Cloud Infrastructure - Trending Now Infrastructure
Oracle Shares Face Sustained Headwinds Amid Strategic Challenges - AD HOC NEWS
3 Forces That Could Shake Oracle Stock - Trefis
Oracle Faces Mounting Legal Challenges Amidst Ambitious Cloud Push - AD HOC NEWS
ORACLE CORPORATION (ORCL) DEADLINE ALERT Bernstein Liebhard LLP Reminds Oracle Corporation Investors of Upcoming Deadline - ACCESS Newswire
Driving innovation in AI transformation and multicloud - Oracle
Oracle Corp Stock (ORCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
4.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):